Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPM1B | O75688 | 1/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.40 |
| ▸ | PPP1CC | P36873 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 3/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6314340 | 1.00 | PPM1B (0.40) | PPM1BPTPN1PPP1CCALDH1A1TSHR | |
| SCHEMBL6313662 | 1.00 | PPM1B (0.40) | PPM1BPTPN1PPP1CCALDH1A1TSHR | |
| SCHEMBL6314331 | 1.00 | PPM1B (0.40) | PPM1BPTPN1PPP1CCALDH1A1TSHR | |
| SCHEMBL6313666 | 1.00 | PPM1B (0.40) | PPM1BPTPN1PPP1CCALDH1A1TSHR | |
| SCHEMBL7860090 | 0.81 | PPM1B (0.39) | PPM1BPTPN1PPP1CCALDH1A1TSHR | |
| SCHEMBL7867734 | 0.81 | PPM1B (0.39) | PPM1BPTPN1PPP1CCALDH1A1TSHR | |
| SCHEMBL12996745 | 0.79 | PPM1B (0.35) | PPM1BPTPN1PPP1CCKDM4EGAA | |
| SCHEMBL12996734 | 0.79 | PPM1B (0.35) | PPM1BPTPN1PPP1CCKDM4EGAA | |
| SCHEMBL6313967 | 0.77 | PPM1B (0.36) | PPM1BPTPN1PPP1CCALDH1A1TSHR | |
| SCHEMBL6313970 | 0.77 | PPM1B (0.36) | PPM1BPTPN1PPP1CCALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6903224-B2 | Substituted 1,3-oxathiolanes | BIOCHEM PHARMA INC. (CA) | 2005-06-07 | — | — | US | claimed |
| US-20030087918-A1 | Synthesis of substituted 1,3-dioxolanes and substituted 1,3-oxathiolanes with antiviral properties | BIOCHEM PHARMA INC. (CA) | 2003-05-08 | — | — | US | claimed |
| US-20010041797-A1 | Processes for preparing substituted 1, 3-oxathiolanes with antiviral properties | BIOCHEM PHARMA INC. (CA) | 2001-11-15 | — | — | US | claimed |
| WO-1994014802-A1 | PROCESS FOR PREPARING SUBSTITUTED 1,3-OXATHIOLANES WITH ANTIVIRAL PROPERTIES | BIOCHEM PHARMA INC. (CA) | 1994-07-07 | — | — | WO | claimed |
| US-6903224-B2 | Substituted 1,3-oxathiolanes | BIOCHEM PHARMA INC. (CA) | 2005-06-07 | — | — | US | disclosed |
| US-20010041797-A1 | Processes for preparing substituted 1, 3-oxathiolanes with antiviral properties | BIOCHEM PHARMA INC. (CA) | 2001-11-15 | — | — | US | disclosed |
| US-6175008-B1 | VIRICIDES FROM REACTION MERCAPTOALDEHYDE WITH ACETOESTER AND 1,4-DITHIANE-2,5-DIOL | BIOCHEM PHARMA INC. (CA) | 2001-01-16 | — | — | US | disclosed |
| US-5684164-A | CHEMICAL INTERMEDIATES | BIOCHEM PHARMA INC. (CA) | 1997-11-04 | — | — | US | disclosed |
| US-5466806-A | Processes for preparing substituted 1,3-oxathiolanes with antiviral properties | BIOCHEM PHARMA INC. (CA) | 1995-11-14 | — | — | US | disclosed |
| WO-1994014802-A1 | PROCESS FOR PREPARING SUBSTITUTED 1,3-OXATHIOLANES WITH ANTIVIRAL PROPERTIES | BIOCHEM PHARMA INC. (CA) | 1994-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030087918-A1 | Synthesis of substituted 1,3-dioxolanes and substituted 1,3-oxathiolanes with antiviral properties | IFNAR1, ZC3HAV1, NUDT1 | PPM1B 1226/4885PTPN1 2322/4885PPP1CC 3222/4885 |
| US-20010041797-A1 | Processes for preparing substituted 1, 3-oxathiolanes with antiviral properties | TYMP, TYMS, PNP | PPM1B 1265/4885PTPN1 2413/4885PPP1CC 2223/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.